190 related articles for article (PubMed ID: 38287168)
1. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma.
Jiang L; Qin J; Dai Y; Zhao S; Zhan Q; Cui P; Ren L; Wang X; Zhang R; Gao C; Zhou Y; Cai S; Wang G; Xie W; Tang X; Shi M; Ma F; Liu J; Wang T; Wang C; Svrcek M; Bardier-Dupas A; Emile JF; de Mestier L; Bachet JB; Nicolle R; Cros J; Laurent-Puig P; Wei M; Song B; Jing W; Guo S; Zheng K; Jiang H; Wang H; Deng X; Chen H; Tian Q; Wang S; Shi S; Jin G; Yin T; Fang H; Chen S; Shen B
Nat Med; 2024 Mar; 30(3):749-761. PubMed ID: 38287168
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study.
Guo JC; Zhang P; Zhou L; You L; Liu QF; Zhang ZG; Sun B; Liang ZY; Lu J; Yuan D; Tan AD; Sun J; Liao Q; Dai MH; Xiao GG; Li S; Zhang TP
EBioMedicine; 2020 May; 55():102767. PubMed ID: 32361251
[TBL] [Abstract][Full Text] [Related]
3. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
4. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of glycolysis-related prognostic score for prediction of prognosis and chemosensitivity of pancreatic ductal adenocarcinoma.
Zhang XP; Chen Q; Liu Q; Wang Y; Wang F; Zhao ZM; Zhao GD; Lau WY; Gao YZ; Liu R
J Cell Mol Med; 2021 Jun; 25(12):5615-5627. PubMed ID: 33942483
[TBL] [Abstract][Full Text] [Related]
6. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
[TBL] [Abstract][Full Text] [Related]
7. A protein-based prognostic model for pancreatic ductal adenocarcinoma: Construction and validation.
Xu Y; Wang Y; Chen Q; Yao T; Qiu J; Ni L; Chen H; Liang T
Pancreatology; 2023 Dec; 23(8):1003-1013. PubMed ID: 37923686
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatics analyses of infiltrating immune cell participation on pancreatic ductal adenocarcinoma progression and in vivo experiment of the therapeutic effect of Shuangshen granules.
Hu J; Jiang J; Xu B; Li Y; Wang B; He S; Ren X; Shi B; Zhang X; Zheng H; Hua B; Liu R
J Ethnopharmacol; 2024 Mar; 322():117590. PubMed ID: 38113986
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma.
Stubbe BE; Madsen PH; Larsen AC; Krarup HB; Pedersen IS; Hansen CP; Johansen JS; Henriksen SD; Thorlacius-Ussing O
Pancreatology; 2023 Aug; 23(5):512-521. PubMed ID: 37230892
[TBL] [Abstract][Full Text] [Related]
11. Identification of an Immune-Related BAT Signature for Predicting Adjuvant Chemotherapy Response and Overall Survival in Patients with Resected Ductal Adenocarcinoma of the Pancreas.
Pu N; Chen Q; Yin H; Zhang J; Zhao G; Habib JR; Chen J; Yu J; Lou W; Wu W
J Gastrointest Surg; 2022 Apr; 26(4):869-886. PubMed ID: 35059985
[TBL] [Abstract][Full Text] [Related]
12. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
13. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
14. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
[TBL] [Abstract][Full Text] [Related]
15. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
Han Y; Drobisch P; Krüger A; William D; Grützmann K; Böthig L; Polster H; Seifert L; Seifert AM; Distler M; Pecqueux M; Riediger C; Plodeck V; Nebelung H; Weber GF; Pilarsky C; Kahlert U; Hinz U; Roth S; Hackert T; Weitz J; Wong FC; Kahlert C
J Hematol Oncol; 2023 Feb; 16(1):7. PubMed ID: 36737824
[TBL] [Abstract][Full Text] [Related]
16. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
18. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
19. Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review.
Vellan CJ; Jayapalan JJ; Yoong BK; Abdul-Aziz A; Mat-Junit S; Subramanian P
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216204
[TBL] [Abstract][Full Text] [Related]
20. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
